Sabry et al., reported that the subcutaneous injection of Apelin-13 (0.1 mol/kg/day, 6 weeks) reduces the mRNA expression of angiotensin II (Ang II)-type 1 receptor (ATR1) in the adipose tissue of rats with T2DM and increases the levels of angiotensin-converting enzyme 2 (ACE2) and NO. This evidence concerns the gene ACE2 and type 2 diabetes mellitus.